Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — H1 FY2019 Earnings Presentation
22 slides from Elixinol Wellness's earnings presentation, Aug 29, 2019
Slide 1: Elixinol Global Limited H1 FY2019 Results Presentation
Elixinol Global Limited H1 FY2019 Results Presentation ASX:EXL | OTCQX:ELLXF ASX:EXL, OTCQX:ELLXF |
Slide 2: Disclaimer
Disclaimer This presentation contains summary information about Elixinol Group Limited (Elixinol) and its subsidiaries and their activities. The information in this presentation does not purport to be complete. It should be read in conjunction with Elixinol’s other periodic and continuous disclosure
Slide 3: Financial Overview
TRUSTED GLOBAL CBD BRAND Financial Overview ASX:EXL, OTCQX:ELLXF | 3
Slide 4: Key highlights for H1 FY2019
Key highlights for H1 FY2019 Revenue from Elixinol Expanding our branded products Strategic global presence increased by 63% to $7.5m and now partnerships of Elixinol branded products via our represents 52% of total USA revenue provides significant global expansion sales teams in the Americas, UK, (
Slide 5: Key highlights for H1 FY2019
Key highlights for H1 FY2019 Strong growth of 19% compared with prior corresponding period Revenue A$ million, 31 December year end • Continued strong revenue growth of 19% in 22.6 H1 FY19 compared with H1 FY18 18.3 15.4 • Revenue growth, excluding private label business, was 34% in H1 FY19 vs H1 FY
Slide 6: Key highlights for H1 FY2019
Key highlights for H1 FY2019 Continued focus on sales of Elixinol branded products Revenue channel mix, Elixinol USA 31 December year end • Continued focus on sales of Elixinol branded products through eCommerce and Retail channels o H1 FY19 sales of Elixinol branded products increased to x% 22% x%
Slide 7: Financial summary
Financial summary Significant investment in building scale to support expected future growth Financial highlights1 Revenue • Revenue increased 19% to $18.3m in H1 FY19 from $15.4m in H1 FY18 H1 FY19 H1 FY18 • Revenue from Elixinol USA branded products increased 63% in H1 FY19 to $7.5m ($4.6m in FY18
Slide 8: Cash flow
Cash flow Strategic investments and capital deployed to scale and build capacity for future growth Cash flow highlights Operating cash flow ($m) H1 FY19 H1 FY18 • Includes $17.3m in payments to build inventory and deposits to Operating activities (28.9) (1.3) secure future inventory in anticipation
Slide 9: Strong financial position
Strong financial position ($m) 30 June 2019 31 December 2018 Strong cash position Current assets • Cash balance of $48.1m to support future growth Cash & cash equivalents 48.1 42.9 Increased working capital to support ongoing growth Trade & other receivables 4.1 3.4 • Inventory on hand increased to
Slide 10: Strategic Priorities
Strategic Priorities ASX:EXL, OTCQX:ELLXF | 10
Slide 11: Elixinol's strategy for long-term growth
Elixinol’s strategy for long-term growth Continued investment in the Elixinol brand, industry leading quality, innovative products and expanding distribution Elixinol’s strategy is focused on the Trusted brand Highest quality Innovative Global following key areas: reputation raw materials products p
Slide 12: Strategic priorities
Strategic priorities Disciplined approach to drive future growth CONTINUED FOCUS ON ELIXINOL GROW ECOMMERCE PRESENCE INNOVATION & TECHNOLOGY BRANDED PRODUCTS • Constructive discussions with large retailers as • Recent investment in eCommerce platform • Pipeline of new products in various stages of w
Slide 13: Multi-channel approach
Multi-channel approach direct to consumer sales To support and drive revenue growth Elixinol’s key focus is on Elixinol Branded Elixinol Branded Elixinol Branded Sales Retail Sales eCommerce Sales Allied Health Professionals natural, specialty & national retailers Elixinol’s Multi-Channel Approach m
Slide 14: A truly global brand
A truly global brand An international distribution platform that can be leveraged to drive growth Elixinol product presence ASX:EXL, OTCQX:ELLXF | 14
Slide 15: Elixinol's product portfolio
Elixinol’s product portfolio A global consumer brand focused on the health and wellness category • CBD-based dietary supplements • Hemp derived food and cosmetics • 45 products* (tinctures, capsules, liposomes, hemp oil, topical • 43 products* (hemp seeds, hemp flour, hemp protein, hemp oil, product
Slide 16: United States - Opportunity and growth
United States - Opportunity and growth Brand leadership position with over 50% sales through branded products • Historic passing of the US Farm Bill de-scheduled hemp from Controlled Substances Act ─ removes substantial barriers to trade and enables mainstream marketing, US CBD Market Size1 promotio
Slide 17: Europe & UK - Opportunity and growth
Europe & UK - Opportunity and growth New market launch started positively • Similar changing legislation to US Europe CBD market size expected growth ─ some countries further ahead, some further behind • Europe’s CBD market expected to grow at a 42% CAGR to $1.7B by 2023 ─ largest European CBD marke
Slide 18: APAC - Opportunity and growth
APAC - Opportunity and growth A very large opportunity • Elixinol owns 51% interest in Elixinol Japan through JV ─ Elixinol Japan has been developing brand presence in Japan since 2016 Opportunity • Utilising expanded production facility in Colorado for expansion throughout APAC • Hemp derived CBD p
Slide 19: Supply Integration
Supply Integration ASX:EXL, OTCQX:ELLXF | 19
Slide 20: Technology
Technology Investing in technology to maximise bioavailability of Elixinol’s hemp derived CBD products • Elixinol will continue to invest in technologies that allow CBD to be more efficacious, cost-effective and useful in formulations with quality and scale • Our experience and reputation has led to
Slide 21: Transparency – from seed to shelf
Transparency – from seed to shelf Supply chain integration and strategic manufacturing partnerships provides Elixinol with a unique positioning, offering consumers and retailers product integrity, traceability and scalability Elixinol Brands Exclusive supply of Strategic partnerships Distribution Ma
Slide 22: For more information please contact
For more information please contact: Ron Dufficy Chief Financial Officer ron.dufficy@elixinolglobal.com www.elixinolglobal.com ASX:EXL, OTCQX:ELLXF | 22